Events › B2B Event
B2B Event
3rd edition
A 3rd edition summit by Hanson Wade focusing on novel obesity therapeutics, metabolic disease, and GLP-1 drug development. It unites R&D leaders, biotech innovators, and clinicians to explore next-generation treatments, clinical trial designs, and drug delivery for obesity management.
Exhibitor mix: Partners and sponsors supporting obesity drug development, likely categorized into expertise and innovation partners.
Filter this event to your ICP.
Dozens of solution providers here. You probably care about 20–30. Tell us your ICP, we'll find them.
Request intelligence →Delivery within 24 hours · $1,250
⚠️ The exhibitor list for this event isn't publicly accessible yet. We'll work on it once you submit a request.
Organizer
Hanson WadePE-backed · London, United Kingdom · Founded 2008
Hanson Wade is a global conference organizer and market intelligence provider focused primarily on the life sciences and biopharma sectors.
Why people attend
Senior drug developers and scientists attend to find partners for clinical trials, drug discovery technologies, and specialized services to accelerate obesity therapeutic development.
Exhibitor categories
Sample matches
Filtered to a Series-B SaaS ICP. Your filter will be different.
Sample Match A
example.com
"Strong ICP match: Series B, EU expansion, VP Engineering and CTO attending."
Sample Match B
example.io
"Mid-stage SaaS with active GTM motion; product-led growth signals align with ICP."
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
████████ ██████
████████.io
"████████████████████████████████████████."
Submit your ICP
to unlock all matches
Speakers
23 speakers at Innovation in Obesity Therapeutics Summit
Also speaking at Biomarkers, CDx & Precision Medicine Europe
Executive Director · Eli Lily
Director, Scientific Strategy · Novo Nordisk
CEO · Halia Therapeutics
+ 7 more speakers at this event.
More events in United States
Frequently asked questions